Humans and dogs have been companions for tens of thousands of years, and their dementia causes are known to be similar. Canine Cognitive Dysfunction Syndrome (CCDS) commonly occurs in dogs over eight and is characterized by amyloid plaque and brain cell death, akin to human Alzheimer’s Disease (AD). Dogs with CCDS exhibit symptoms similar to human AD, including memory and sleep disorders, changes in social behavior, disorientation, and incontinence. The pathogenesis of AD and CCDS is likely similar, suggesting that future treatments may be effective for both.

Since 1998, GNT Pharma researchers have studied Alzheimer’s disease causes and developed treatment technologies. Our discovery, Crisdesalazine, is a potent antioxidant and anti-inflammatory agent that inhibits mPGES-1, reducing brain free radicals, inflammation, amyloid plaque, neuron loss, and cognitive dysfunction in dementia mouse models. Its effectiveness has been demonstrated in improving performance.

We established GNT Animal Health (GAH) and conducted clinical trials to develop Crisdesalazine as a treatment for CCDS. Working with major animal hospitals, including Seoul National University’s College of Veterinary Medicine, GAH confirmed Crisdesalazine’s outstanding safety and effectiveness. We proudly launched GedaCure® in South Korea—the world’s first CCDS medicine that improves cognitive function and slows disease progression. We hope GedaCure® will help dogs with CCDS and bring joy to their owners. GAH remains committed to advancing high-quality treatments that enhance the health and happiness of companion animals and their families.